GSK’s DoJ Settlement Requires Execs To Forfeit Bonuses If Misconduct Occurs
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline pleads guilty to promoting Paxil and Wellbutrin off-label and failing to report Avandia safety data to FDA; civil portion of settlement resolves off-label and kickback allegations involving nine products. New corporate integrity agreement gives OIG authority to require a recall.